BETRF:OTC-BetterLife Pharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.086

Change

-0.01 (-5.49)%

Market Cap

USD 0.01B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

-2.01 (-2.14%)

USD 34.52B
UCBJF UCB SA

N/A

USD 33.97B
ARGNF argenx SE

N/A

USD 32.04B
GNMSF Genmab A/S

-2.20 (-0.93%)

USD 16.79B
ZLDPF Zealand Pharma A/S

-7.00 (-5.30%)

USD 9.62B
IVBIY IVBIY

N/A

USD 8.92B
SBMFF Sino Biopharmaceutical Limited

+0.04 (+9.81%)

USD 7.86B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.85B
WXIBF WuXi Biologics

N/A

USD 7.06B
WXXWY WuXi Biologics (Cayman) Inc

+0.16 (+4.65%)

USD 7.06B

ETFs Containing BETRF

XSOE WisdomTree Emerging Marke.. 1.63 % 0.32 %

+1.19 (+3.22%)

N/A
SPEM SPDR® Portfolio Emerging.. 1.40 % 0.12 %

+1.30 (+3.22%)

USD 9.53B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 79.17% 87% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.17% 87% B+ 91% A-
Trailing 12 Months  
Capital Gain 50.88% 83% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.88% 83% B 86% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -32.47% 16% F 6% D-
Dividend Return -32.47% 16% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.46% 74% C 58% F
Risk Adjusted Return -80.26% 19% F 8% B-
Market Capitalization 0.01B 53% F 39% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.